Results 41 to 50 of about 15,191 (179)

L-Asparaginase from Penicillium sizovae Produced by a Recombinant Komagataella phaffii Strain

Pharmaceuticals, 2022
L-asparaginase is an important enzyme in the pharmaceutical field used as treatment for acute lymphoblastic leukemia due to its ability to hydrolyze L-asparagine, an essential amino acid synthesized by normal cells, but not by neoplastic cells.
Marcela Freitas, Paula Souza, Mauricio Homem-de-Mello, Yris M. Fonseca-Bazzo, Damaris Silveira, Edivaldo X. Ferreira Filho, Adalberto Pessoa Junior, Dipak Sarker, David Timson, João Inácio, Pérola O. Magalhães   +10 more
doaj   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

A Study on L-Asparaginase of Nocardia levis MK-VL_113

The Scientific World Journal, 2012
An enzyme-based drug, L-asparaginase, was produced by Nocardia levis MK-VL_113 isolated from laterite soils of Guntur region. Cultural parameters affecting the production of L-asparaginase by the strain were optimized.
Alapati Kavitha, Muvva Vijayalakshmi
doaj   +1 more source

Metabolic feature profiling and metabolic vulnerability in acute lymphoblastic leukemia

Interdisciplinary Medicine, EarlyView.
For the first time, our study develops a novel metabolic classification and subtyping program, metabolic reprogramming‐based classifier for acute lymphoblastic leukemia, using internal PDT‐ALL‐2016 and external cohorts, which dissects metabolic profiling, clinical outcome, and therapeutic vulnerability for precision metabolic intervention in ALL ...
Xiaojie Liang, Zihong Cai, Bingqing Tang, Zicong Huang, Baiwei Luo, Bingyu Lin, Yunong Yang, Zhihao Jin, Xiaoqing Li, Xiuli Xu, Yeling Deng, Chaoran Lin, Liang Wang, Hongsheng Zhou   +13 more
wiley   +1 more source

The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis

Health Economics Review, 2019
Background L-asparaginase is a key component of treatment for patients with acute lymphoblastic leukaemia (ALL) in the UK. Commonly used forms of asparaginase are native E.
Xingdi Hu, Kingsley P. Wildman, Subham Basu, Peggy L. Lin, Clare Rowntree, Vaskar Saha   +5 more
doaj   +1 more source

Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report

Haematologica, 2019
Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten trial groups contributed remission ...
Benjamin O. Wolthers, Thomas L. Frandsen, Chirag J. Patel, Rachid Abaji, Andishe Attarbaschi, Shlomit Barzilai, Antonella Colombini, Gabriele Escherich, Marie Grosjean, Maja Krajinovic, Eric Larsen, Der-Cherng Liang, Anja Möricke, Kirsten K. Rasmussen, Sujith Samarasinghe, Lewis B. Silverman, Inge M. van der Sluis, Martin Stanulla, Morten Tulstrup, Rachita Yadav, Wenjian Yang, Ester Zapotocka, Ramneek Gupta, Kjeld Schmiegelow   +23 more
doaj   +1 more source

A Case of Cutaneous B Lymphoblastic Lymphoma With Multiple Cutaneous Tumors

JEADV Clinical Practice, EarlyView.
ABSTRACT A 17‐year‐old Japanese male patient was referred to our hospital due to an erythematous tumor on part of the right mandible that had developed 3 months earlier, and similar tumors had appeared on the trunk and lower extremities. A complete blood count showed no specific abnormalities.
Tomomichi Shimizu, Akio Kondoh, Fumikazu Yamazaki, Osamu Yamamoto, Tomotaka Mabuchi   +4 more
wiley   +1 more source

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

ESMO Open, 2020
With recent prospective clinical trials that used paediatric regimens with multiple doses of pegylated form of asparaginase (PEG asparaginase) in adults reporting significantly improved survival compared with historical data with regimens that used less ...
Kjeld Schmiegelow, Patrick W Burke, Dieter Hoelzer, Jae H Park, Dan Douer   +4 more
doaj   +1 more source

Dynamic early biomarkers predict outcomes in pediatric Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis

Pediatric Investigation, EarlyView.
This study elucidates the critical pathogenic mechanisms of pediatric Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis (EBV‐HLH), where EBV infection triggers a cytokine storm leading to immune cell hyperactivation and tissue damage. Dynamic plasma biomarkers (EBV‐DNA, ferritin, and interferon‐γ) effectively predict treatment response ...
Feifei Liu, Qing Zhang, Sitong Chen, Yunze Zhao, Dong Wang, Hongyun Lian, Honghao Ma, Tianyou Wang, Rui Zhang, Zhigang Li   +9 more
wiley   +1 more source

Asparaginase-Induced Hypertriglyceridemia Presenting as Pseudohyponatremia during Leukemia Treatment

Case Reports in Pediatrics, 2014
Asparaginase is a chemotherapeutic agent used to induce disease remission in children with acute lymphoblastic leukemia (ALL). We describe the cases of two females with ALL who developed pseudohyponatremia as a presentation of hypertriglyceridemia ...
Ashley Hinson, Dorothee Newbern, Corinne M. Linardic   +2 more
doaj   +1 more source